MERIAN GLOBAL INVESTORS UK Ltd lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 841.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 269,170 shares of the life sciences company’s stock after acquiring an additional 240,569 shares during the quarter. MERIAN GLOBAL INVESTORS UK Ltd’s holdings in Illumina were worth $83,628,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc grew its position in shares of Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after buying an additional 188,516 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Illumina by 66,581.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares during the period. Jennison Associates LLC grew its position in shares of Illumina by 13.5% in the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares during the period. Geode Capital Management LLC grew its position in shares of Illumina by 10.1% in the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after buying an additional 170,046 shares during the period. Finally, Norges Bank purchased a new stake in shares of Illumina in the 4th quarter worth about $514,627,000. 90.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ILMN stock opened at $310.70 on Friday. Illumina, Inc. has a one year low of $261.61 and a one year high of $372.61. The stock has a market cap of $45.55 billion, a P/E ratio of 54.65, a PEG ratio of 2.13 and a beta of 1.15. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27.
A number of research firms have recently weighed in on ILMN. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Canaccord Genuity reissued a “buy” rating and set a $350.00 price objective (down from $360.00) on shares of Illumina in a research report on Friday, April 26th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 price objective on the stock in a research report on Tuesday, April 2nd. OTR Global downgraded shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. Finally, Deutsche Bank downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a research report on Friday, January 25th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Illumina currently has an average rating of “Buy” and an average price target of $353.58.
In other news, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $314.45, for a total transaction of $38,991.80. Following the sale, the senior vice president now owns 8,210 shares of the company’s stock, valued at approximately $2,581,634.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $300.00, for a total transaction of $990,000.00. Following the sale, the director now directly owns 341,568 shares in the company, valued at approximately $102,470,400. The disclosure for this sale can be found here. Insiders have sold a total of 50,329 shares of company stock worth $15,648,675 over the last three months. 0.38% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “MERIAN GLOBAL INVESTORS UK Ltd Acquires 240,569 Shares of Illumina, Inc. (ILMN)” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/17/merian-global-investors-uk-ltd-acquires-240569-shares-of-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Average Daily Trade Volume – ADTV
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.